logo







Home>Companies>Personal-genome-diagnostics


Personal genome diagnostics

Personal genome diagnostics



Personal Genome Diagnostics is a biotechnology company that develops cancer genome testing products aimed at providing actionable insights from genomic data to enhance cancer treatment and research.
Sign up today to get real-time market insights on Personal genome diagnostics and hundreds of other pre-IPO companies



Personal genome diagnostics Overview

Baltimore, MD, United States
2010
Biotech
https://www.personalgenome.com



Personal genome diagnostics Live Market Data

$00000000
$00000000




Personal genome diagnostics Funding Rounds



RoundDateAmount RaisedValuationInvestorsSources
Merger/Acquisition2/18/2022
Series C2/10/2021
Series 17/24/2020
Series B1/4/2018
Series A10/28/2015
Seed Round
4/2/2014




Personal genome diagnostics Investors



InvestorInvestment RoundsLead PartnerInitial InvestmentOther Notable Investments
New Enterprise AssociatesSeries B, Series C, Series ASeries B (2018-01-04)
Bristol-Myers Squibb (NYS: BMY)Series BSeries B (2018-01-04)
Sands CapitalSeries CSeries C (2021-02-10)




Personal genome diagnostics 409a Valuations



DatePrice per shareEst. ValuationFilling
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Sign up to access Personal genome diagnostics data




Personal genome diagnostics Filings



TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign up to access Personal genome diagnostics data




Latest Personal genome diagnostics News







Caplight Logo




Use CasesInvestorsEmployees

CompaniesAll Companies

LegalPrivacy PolicyTerms of UseBrokerCheckForm CRS


DisclaimerAll investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.